Analyst Naz Rahman of Maxim Group reiterated a Buy rating on Vivani Medical, retaining the price target of $4.00.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Naz Rahman has given his Buy rating due to a combination of factors that highlight Vivani Medical’s promising prospects. The company is advancing its NPM-139 semaglutide implant, which offers a unique six-month administration cycle, potentially addressing patient compliance issues associated with more frequent dosing schedules. This innovation could capture a significant market opportunity, given the well-established efficacy and safety profile of semaglutide, known from products like Ozempic and Wegovy.
Additionally, the recent acquisition of Metsera by Pfizer underscores the high value placed on differentiated, long-duration obesity treatments. This transaction, involving a substantial bidding war, suggests strong interest from major pharmaceutical companies in such assets, which bodes well for Vivani’s strategy. With sufficient financial resources to support its operations and clinical trials, Vivani is well-positioned to capitalize on its innovative approach, reinforcing Naz Rahman’s confidence in a Buy recommendation.
VANI’s price has also changed moderately for the past six months – from $1.050 to $1.355, which is a 29.05% increase.